Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:CLSD NASDAQ:DYAI NASDAQ:ITRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.74+1.5%$0.77$0.38▼$115.57$8.65M0.711.57 million shs28,322 shsCLSDClearside Biomedical$0.34-7.7%$0.55$0.29▼$1.65$28.85M2.11502,382 shs1.12 million shsDYAIDyadic International$0.95+3.3%$0.95$0.71▼$2.20$33.34M0.95121,169 shs71,027 shsITRMIterum Therapeutics$0.64-5.4%$0.84$0.63▼$3.02$30.22M3.04904,500 shs700,383 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%+0.92%+7.65%+24.10%-98.78%CLSDClearside Biomedical0.00%-8.76%-4.32%-50.00%-63.61%DYAIDyadic International0.00%+5.90%-8.33%-8.33%-31.25%ITRMIterum Therapeutics0.00%-6.13%-7.54%-29.50%-42.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma2.941 of 5 stars3.55.00.00.00.60.01.9CLSDClearside Biomedical2.9485 of 5 stars4.15.00.00.02.40.00.0DYAIDyadic International3.4311 of 5 stars3.55.00.00.02.73.30.0ITRMIterum Therapeutics3.1666 of 5 stars3.55.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0048,352.22% UpsideCLSDClearside Biomedical 2.17Hold$4.201,138.57% UpsideDYAIDyadic International 3.00Buy$6.00530.45% UpsideITRMIterum Therapeutics 3.00Buy$9.001,306.25% UpsideCurrent Analyst Ratings BreakdownLatest AEON, ITRM, CLSD, and DYAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$5.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$2.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$3.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ACLSDClearside Biomedical$1.66M16.04N/AN/A($0.62) per share-0.55DYAIDyadic International$3.42M10.07N/AN/A($0.01) per share-95.17ITRMIterum TherapeuticsN/AN/AN/AN/A($0.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$6.084.13N/AN/AN/AN/A-994.63%N/ACLSDClearside Biomedical-$34.35M-$0.37N/AN/AN/A-665.19%N/A-124.15%11/11/2025 (Estimated)DYAIDyadic International-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)Latest AEON, ITRM, CLSD, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million8/8/2025Q2 2025CLSDClearside Biomedical-$0.12-$0.06+$0.06-$0.06$0.50 million$0.49 million8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22CLSDClearside BiomedicalN/A3.873.87DYAIDyadic International5.402.022.02ITRMIterum TherapeuticsN/A2.692.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%CLSDClearside Biomedical18.75%DYAIDyadic International27.95%ITRMIterum Therapeutics9.21%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%CLSDClearside Biomedical6.70%DYAIDyadic International29.50%ITRMIterum Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.64 million74.37 millionNot OptionableCLSDClearside Biomedical3078.51 million73.25 millionOptionableDYAIDyadic International736.19 million25.51 millionOptionableITRMIterum Therapeutics1044.66 million43.59 millionNot OptionableAEON, ITRM, CLSD, and DYAI HeadlinesRecent News About These CompaniesIterum Therapeutics PLC: Iterum Therapeutics launches ORLYNVAH, the first and only oral penem antibiotic in the U.S.August 20, 2025 | finanznachrichten.deIterum Therapeutics announces U.S. commercial launch of ORLYNVAHAugust 20, 2025 | msn.comIterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.August 20, 2025 | globenewswire.comIterum Therapeutics PLC (NASDAQ:ITRM) Director Michael W. Dunne Purchases 15,000 SharesAugust 13, 2025 | insidertrades.comIterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | msn.comITRM Reports ResultsAugust 5, 2025 | fool.comIterum Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 5, 2025 | globenewswire.comIterum Therapeutics Q2 Earnings PreviewAugust 4, 2025 | msn.comInsights Ahead: Iterum Therapeutics's Quarterly EarningsAugust 4, 2025 | benzinga.comIterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025July 29, 2025 | globenewswire.comIterum Therapeutics plc (ITRM) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comIterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMIterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comIterum Therapeutics appoints Coyne as CCOJune 30, 2025 | msn.comIterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial GrowthJune 30, 2025 | globenewswire.comITRM - Iterum Therapeutics PLC Chart - MorningstarJune 25, 2025 | morningstar.comMIterum Therapeutics Announces Publication of REASSURE Trial in NEJM EvidenceJune 25, 2025 | globenewswire.comIterum Therapeutics PLC: Iterum Therapeutics Announces Partnership for Commercialization ServicesJune 11, 2025 | finanznachrichten.deIterum Therapeutics Announces Partnership for Commercialization ServicesJune 11, 2025 | globenewswire.comIterum Therapeutics Announces Extension of Term of Promissory NoteMay 19, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEON, ITRM, CLSD, and DYAI Company DescriptionsAEON Biopharma NASDAQ:AEON$0.74 +0.01 (+1.54%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.01 (+1.75%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Clearside Biomedical NASDAQ:CLSD$0.34 -0.03 (-7.73%) Closing price 04:00 PM EasternExtended Trading$0.35 +0.01 (+2.03%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Dyadic International NASDAQ:DYAI$0.95 +0.03 (+3.30%) Closing price 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.45%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Iterum Therapeutics NASDAQ:ITRM$0.64 -0.04 (-5.44%) Closing price 04:00 PM EasternExtended Trading$0.65 +0.01 (+1.56%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
